Exelixis Employs Novel Adaptive Trial Design To Evaluate Cabozantinib In Multiple Cancers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Exelixis Inc.'s investigational cancer drug cabozantinib demonstrated activity in patients with nine kinds of cancer as part of a single Phase II trial that employs a novel adaptive randomized discontinuation design. The company presented updated data from the trial in three sessions at the American Society of Clinical Oncology meeting June 3-7 in Chicago.